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dicted using a Markov model, which tracked cohort
movements across fracture outcome states. We ran 50
consecutive cohorts, starting each year of age 50 through
99, each with a 10-year follow up. Average cost at each
individual patient age was adjusted by osteoporosis attri-
bution rates; then the population of women within ages
50–100 was multiplied by average cost to determine total
cost by age, within each year (2000–2009). Because frac-
ture incidence rates were unavailable, costs of other frac-
tures and total costs of osteoporosis in males were esti-
mated by multiplying base year costs by the respective
population increases over time. RESULTS: Discounted
costs of osteoporosis were over $1 billion in 2000 and in-
creased to $1.21 billion (21%) by 2009. The greatest cost
increases were for age groups 50–64 and 85. Total cost
for the decade exceeded $11.1 billion. CONCLUSIONS:
Osteoporosis is predicted to have substantial and increas-
ing impacts on Florida’s healthcare resources. This infor-
mation may contribute to health policy discussions in
Florida.
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Since osteoporosis is a silent disease until fracture occurs,
identification of patients with a high lifetime risk of fur-
ther developing this disorder, using bone densitometry, is
widely recognized as the gold standard diagnostic proce-
dure. Nonetheless, measuring Bone Mineral Density (BMD)
for the whole population has proved to be either unfeasi-
ble and/or cost inefficient as public health resources are
limited. Therefore several attempts have been made to
develop tools aiming at selecting persons with low BMD
who should be referred for bone densitometry. The Sim-
ple Calculated Osteoporosis Risk Estimation (SCORE),
has been just designed for this purpose. OBJECTIVE:
The main objective of our study was to assess the poten-
tial efficiency of this instrument for a more rational use
of bone densitometry by excluding subjects who are un-
likely to need such a procedure. Our sample consisted of
4035 white women aged at least 45 years, recruited ret-
rospectively from a Belgian outpatient osteoporosis cen-
ter. BMD measures, using DEXA technology were col-
lected at the regions of the lumbar spine (L2-L4), the
femoral neck and the total hip. METHOD: At, at least
one of these sites, 47% of our sample had a low BMD
(defined as t-score  2 SD) and more than 32 % were
found osteoporotic, according to WHO definition
(t-score  2.5 SD). At the recommended SCORE cut-
point of 6, 18% of the patients would not be recom-
mended for densitometry. Among those, 10.9% were
misclassified as they did have osteoporosis at, at least one
of the considered sites. Considering each site separately,
the negative predictive errors of SCORE, when failing to
detect osteoporosis, were only 1% for the total hip, 3.2%
for the femoral neck and 8.8%for the lumbar spine.
CONCLUSIONS: We conclude that although the overall
accuracy of SCORE had demonstrated to be quite poor
as a diagnostic tool, from a resource allocation stand
point, this instrument could be used with relative confi-
dence to exclude patients who do not need a BMD mea-
surement, opening the perspective of substantial savings
in comparison to a mass screening strategy.
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Osteoporosis is a major public health problem in post-
menopausal women. Identifying patients at risk of devel-
oping an osteoporosis related fracture remains one of the
challenges of the next decades. Although it is widely rec-
ognized that the “gold standard” procedure for os-
teoporosis diagnosis is bone densitometry, economic is-
sues or availability of the densitometers may prevent its
use under a mass screening scenario. A risk assessment
instrument, the Simple Calculated Osteoporosis Risk Es-
timation (SCORE), has been developed to be used for se-
lecting women likely to have low bone mass density
(BMD) for referring for bone densitometry. Low BMD
was defined as 2 standard deviations or more below the
mean of young healthy adult. The promises shown by the
original validation of SCORE have to be further tested
on different populations. A couple of published studies
did not reach the same level of satisfaction. OBJECTIVE:
The aim of our study is to evaluate this prescreening tool
in a large sample of Caucasian women, at different levels
of BMD and at various sites of measurement. METHOD:
We gathered medical data on 4035 patients aged 45
years or more, either consulting spontaneously or re-
ferred for a BMD measurement to an outpatient os-
teoporosis center located in Liege, Belgium. BMD mea-
sures, using DEXA technology, were listed at the hip
(both total and neck) and the lumbar spine (L2-L4). RE-
SULTS: More than 47% of our sample presented with
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low BMD at, at least one of the sites considered. At the
recommended cutoff point of 6, SCORE had a sensitivity
of 91.5% to detect a low BMD at any site, a specificity of
26.5%, a positive predictive value of 52.8% and a nega-
tive predictive value of 77.7%. For the hip the associated
indicators of SCORE ability to identify low BMD reached
respectively 97.4%, 21.1%; 20.1% and 97.5%. For the
femoral neck the parameters yielded were respectively
95.9%, 23.8%, 34.4% and 93.4%. At the lumbar spine
SCORE performed less well. Area under the Receiver
Operating Characteristic curve to detect low BMD at the
total hip and the femoral neck were 0.760 and 0.738 re-
spectively. CONCLUSIONS: In view of these results we
can conclude that, notwithstanding the high values of
sensitivity achieved (which are even higher in our experi-
ence than those reported in the princeps paper), SCORE
specificity is too low to be used as a diagnostic tool for
screening patients at high risk to later develop osteo-
porosis.
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Osteoporosis is a public health problem that not only ex-
erts significant morbidity and mortality to society but
also a heavy financial burden. An effective strategy for
controlling this disease is identifying high-risk population
for early intervention. OBJECTIVES: The purpose of this
study was to determine the age group most cost-effective
to screen for osteoporosis in elderly women. METH-
ODS: The study population is women from 50 to 79
years old, who have not incurred a bone fracture. All
costs and life-years saved from intervention were calcu-
lated using the 5-year backward induction, incorporating
the DEALE method. The analysis is done from the per-
spective of society and a 3% discount rate is used. The
variables in the analysis were extracted from the litera-
ture. RESULTS: The cost to save one life-year from
screening for osteoporosis ranges from $97,208 to
$180,533. The variable most sensitive in the model is the
cost of an annual bone scan; a 20% variation in price of
a bone scan shifts the cost-effectiveness ratio by 19 to
22%. If a bone scan is required every 5 years, this inter-
vention would be cost-effective for women 65 to 79 years
old, assuming an intervention is cost-effective if it costs
$50,000 or less per life-year saved. CONCLUSIONS:
The results in this model demonstrate that screening for
osteoporosis in the elderly female population is not cost-
effective between 50 to 79 years. Future research may in-
clude following a cohort of women in this age range and
assess all cost related to providing osteoporosis care for a
more complete account of total costs to society.
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OBJECTIVE: To evaluate age-specific prevalence rates
for pharmacological treatment and prevention of os-
teoporosis among commercially insured women 18 years
or older in a managed care environment. METHODS:
Administrative pharmacy claims data from four health
plans between July 1, 1997 and June 30, 1998 were used
to determine the number of women who received at least
one prescription for therapy indicated for the treatment
or prevention of osteoporosis. Therapies indicated for the
treatment of osteoporosis included alendronate 10 mg
and intranasal calcitonin. Therapies indicated for the pre-
vention of osteoporosis included alendronate 5 mg and
raloxifene. Use of hormone replacement therapy (HRT)
was also included as possible osteoporosis prevention
therapy. Study subjects must have been continuously en-
rolled for 12 months both prior to and following their
study enrollment date. RESULTS: Over 15% of the study
population (N  84,587 members) received osteoporosis
therapy. The prevalence of osteoporosis treatment with
alendronate 10 mg or intranasal calcitonin was 0.5%.
The prevalence of osteoporosis prevention with alen-
dronate 5 mg, raloxifene, or HRT was 15.2%. Os-
teoporosis therapy was most prevalent among women
aged 50 to 59. As age increased beyond 59 years, the use
of HRT tapered off while the use of alendronate, ralox-
ifene, and intranasal calcitonin increased. Of those who
received osteoporosis therapy, 96% received HRT, 2.1%
received alendronate 10 mg, 0.9% received intranasal
calcitonin, 0.6% received raloxifene, and 0.4% received
alendronate 5 mg. CONCLUSION: Although rates of
therapy in the four health plans echo national estimates,
the number of women receiving osteoporosis prevention
therapy remains low in comparison to the number of
women at risk for the disease.
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Generic measures of health status provide an important
common denominator for comparing the burden of ill-
ness across diseases. OBJECTIVES: To document illness
burden of early rheumatoid arthritis (RA) on health re-
